News

September 8, 2017

FDA Grants Orphan Drug Status to INN-108 as an Ulcerative Colitis Therapy for Children

News

The U.S. Food and Drug Administration has granted orphan drug status to INN-108 as a treatment for children with ulcerative colitis, its maker, Innovate Biopharmaceuticals, announced in a press release. Regulators grant orphan drug designation to treatments ... Read more

September 7, 2017September 7, 2017

Cara, First Precision ‘Poop Tech’ App for Digestive Health, Raises $2 Million in Seed Funding

News

Cara, a Berlin-based digital health startup, has raised $2 million in seed funding led by Atlantic Labs to launch the first precision medicine solution for digestive health. The company says ... Read more

September 6, 2017September 6, 2017

Canada Extends Insurance Coverage of Humira for Ulcerative Colitis Patients

News

Canadian health authorities have decided to increase national coverage of Humira (adalimumab) through its federal Non-Insured Health Benefits (NIHB) program, which provides coverage to nearly one million status First Nations ... Read more

September 5, 2017September 5, 2017

Asthma Identified As Potential Risk Factor for IBD, Canadian Study Suggests

News

Asthma increases the risk for Crohn’s disease and early- and late-onset ulcerative colitis, a Canadian population-based study suggests. The study, “Asthma Is Associated With Subsequent Development of Inflammatory Bowel Disease: A ... Read more

September 1, 2017

Bowel Disease Increases Risk of Heart Disease and Death, Spanish Study Reports

News

People with bowel diseases such as Crohn’s and ulcerative colitis are at increased risk of developing cardiovascular disease and of dying, a large-population Spanish study reports. Cardiovascular diseases are a leading cause of ... Read more

August 31, 2017

Takinib Might Be Starting Point for Therapies Targeting Inflammatory Diseases, Study Finds

News

Takinib, an inhibitor of the protein TAK1, was found to interrupt the inflammatory response central to a variety of autoimmune disorders, such as Crohn’s disease, research shows. The study, “Takinib, a Selective ... Read more

August 30, 2017August 30, 2017

FDA Approves Humira Biosimilar Cyltezo for Ulcerative Colitis, Crohn’s Disease, Other Illnesses

News

The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim‘s Cyltezo— a biosimilar of Abbvie’s Humira (adalimumab) — to treat Crohn’s disease, ulcerative colitis and a host of other diseases ranging from ... Read more

August 29, 2017August 29, 2017

European Commission Approves Biosimilar Imraldi for Crohn’s Disease and Ulcerative Colitis

News

The European Commission has approved Imraldi, an adalimumab biosimilar referencing AbbVie’s Humira — making the medication available to treat the same therapeutic indications as Humira, including Crohn’s disease, pediatric Crohn’s disease and ... Read more

August 28, 2017August 28, 2017

Exclusive Enteral Nutrition Induces Remission in Crohn’s Disease As Effectively as Corticosteroids, Study Finds

News

Exclusive enteral nutrition (EEN) is just as effective as corticosteroids in inducing remission in Crohn’s disease patients — including children — and with fewer adverse effects. According to a review analysis, ... Read more

August 25, 2017

Chronic Inflammatory Disorders Associated with Higher Risk for Cardiovascular Events

News

Chronic inflammatory diseases are associated with an increased risk of cardiovascular and metabolic events, such as stroke and diabetes, particularly for patients on corticosteroids or NSAIDs (non-steroidal anti-inflammatory drugs), a ... Read more